Dendritic cells program non‐immunogenic prostate‐specific T cell responses beginning at early stages of prostate tumorigenesis
- 12 January 2007
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 67 (5) , 536-546
- https://doi.org/10.1002/pros.20549
Abstract
BACKGROUND Prostate cancer promotes the development of T cell tolerance towards prostatic antigens, potentially limiting the efficacy of prostate cancer vaccines targeting these antigens. Here, we sought to determine the stage of disease progression when T cell tolerance develops, as well as the role of steady state dendritic cells (DC) and CD4+CD25+ T regulatory cells (Tregs) in programming tolerance. METHODS The response of naïve HA‐specific CD4+ T cells were analyzed following adoptive transfer into Pro‐HA × TRAMP transgenic mice harboring variably‐staged HA‐expressing prostate tumors on two genetic backgrounds that display different patterns and kinetics of tumorigenesis. The role of DC and Tregs in programming HA‐specific CD4 cell responses were assessed via depletion. RESULTS HA‐specific CD4 cells underwent non‐immunogenic responses at all stages of tumorigenesis in both genetic backgrounds. These responses were completely dependent on DC, but not appreciably influenced by Tregs. CONCLUSIONS These results suggest that tolerogenicity is an early and general property of prostate tumors. Prostate 67: 536–546, 2007.Keywords
This publication has 47 references indexed in Scilit:
- Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinomaThe Prostate, 2007
- Therapeutic cancer vaccinesCurrent Opinion in Immunology, 2006
- CD4+CD25+ T Cells Regulate Virus-specific Primary and Memory CD8+ T Cell ResponsesThe Journal of Experimental Medicine, 2003
- Toll Pathway-Dependent Blockade of CD4 + CD25 + T Cell-Mediated Suppression by Dendritic CellsScience, 2003
- The CD8α+ Dendritic Cell Is Responsible for Inducing Peripheral Self-Tolerance to Tissue-associated AntigensThe Journal of Experimental Medicine, 2002
- Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte ResponsesThe Journal of Experimental Medicine, 2001
- Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in VivoThe Journal of Experimental Medicine, 2001
- Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytomaEuropean Journal of Immunology, 1996
- Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor.The Journal of Experimental Medicine, 1994
- An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues.The Journal of Experimental Medicine, 1993